A13 Abstracts control group included 25 propensity score matched clients (95,054 lives) not enrolled in the program. In the study group, the average total cost per prescription (normalized to 90-day supply) was significantly lower in 90-day retail than in mail service and 30-day retail ($165.9 vs. $170.65 vs. $185.9). The generic utilization rate in 90-day retail was higher than in mail service but lower than 30-day retail (38.36% vs. 37.38% vs.
1 Thomson Medstat, Ann Arbor, MI, USA, 2 Thomson Medstat, Washington, DC, USA, 3 Research Data Solutions, Boston, MA, USA OBJECTIVES: Estimate out-of-pocket pharmacy expenditures for elderly retirees with employer-sponsored coverage, under the standard Medicare drug plans that began on January 1, 2006. METHODS: Data came from the Medstat MarketScan Medicare Database, for 2004. Data included all medical and pharmacy claims for 1,220,902 seniors enrolled in retiree plans offered by large employers. (About 30% of non-institutionalized Medicare enrollees have retiree coverage.) Payments covered by the Medicare program and by private insurance were included. Analyses focused on 30,681 patients with diagnoses of depression, anxiety disorder, or schizophrenia in 2004. We estimated the out-of-pocket payments that would have been incurred by these beneficiaries, if the Medicare drug law had been in effect during 2004. We also estimated how long it may take to enter the "donut hole" where coverage stops (i.e., that period during which total pharmacy expenditures range from $2251 to $5100). RESULTS: Mean total pharmacy payments for these mental health patients were higher than payments for other patients with retiree coverage ($4491 for depression patients, $3364 for anxiety patients, and $5321 for schizophrenia patients, versus $2587 for the average Medicare beneficiary). The average mental health patient filled over 50 prescriptions for all medical problems. More than 30% would have entered the donut hole. Schizophrenia patients would have entered after about 4 months (in April). Depression patients would fall into the donut hole after about 6 months, while anxiety patients would enter after about 9 months, on average. Average out-of-pocket pharmacy payments under the new law would have ranged from $1858 for anxiety patients to $2407 for schizophrenia patients. CON-CLUSIONS: Most patients with these psychiatric conditions will face high out of pocket costs, and will be faced with a donut hole of no coverage. Implications for adherence to pharmacotherapy and overall health should be considered by doctors and policy makers.
HE3 DIFFERENTIAL RACIAL AND ETHNIC DISPARITIES IN HEALTH EXPENDITURE AND SELF-PERCEIVED HEALTH STATUS IN THE UNITED STATES
Wang J 1 , Mullins CD 2 , Zuckerman IH 2 , White-Means SI 1 , Arreola R 1 , Hufstader MA 1 , Hutchison L 1 , Walker GD 1 1 University of Tennessee, Memphis, TN, USA, 2 University of Maryland Baltimore, Baltimore, MD, USA OBJECTIVES: The research objective is to examine whether there are racial and ethnic disparities in health expenditures and health status. Health expenditure and health status are examined together because theoretically higher spending on health care services should lead to better health status. METHODS: The data were drawn from a nationally representative sample of noninstitutionalized U.S. civilians in the Medical Expenditure Panel Survey (1996 and 2001) . The racial and ethnic disparities were examined separately by comparing non-Hispanic whites, non-Hispanic blacks, and Hispanic whites (Hispanic blacks were excluded due to small sample size). Disparities in self-perceived health status (poor, fair, good, very good, and excellent) were compared across racial and ethnic groups using an ordered logistic regression. Disparities in health expenditure were compared using linear regression (A two-part model was also used to confirm the findings). RESULTS: The study sample included 31,258 non-Hispanic whites, 7349 non-Hispanic black, and 11,248 Hispanic whites. There was an overall significantly better self-perceived health status among non-Hispanic whites than non-Hispanic blacks and Hispanic whites: non-Hispanic blacks were 79.29% as likely to report a better self-perceived health status category compared to non-Hispanic whites (P < 0.01); Hispanic whites were 77.06% as likely to report a better selfperceived health status category compared to non-Hispanic whites (P < 0.01). Overall, non-Hispanic blacks and Hispanic whites spent $690 less (P < 0.01) and $1365 (P < 0.01) less than non-Hispanic whites every year. The racial disparities in health expenditures and self-perceived health status were significant after adjusting for confounders; ethnic disparities in health expenditures were still significant but ethnic disparities in health status were not significant. CONCLUSIONS: Compared with non-Hispanic whites, non-Hispanic blacks have lower health expenditure and worse self-perceived health status; Hispanic whites have lower expenditures but similar self-perceived health status. Further analysis is warranted to examine the causes for different patterns of racial and ethnic disparities. Abstracts based on primary ICD-9-CM discharge diagnosis of ICH (431.xx). Patient-level information included demographics (including race/ethnicity: White, Black, Hispanic, Asian), hospital characteristics, comorbidities, primary payer, admission source, discharge destination, DRG, length of stay (LOS), and hospital charges. Costs were estimated by applying hospitalspecific cost-to-charge ratios to charges. Adjusted LOS and cost (controlling for age, in-hospital mortality, and other covariates) by race/ethnicity were estimated using multivariate least-squares regression. RESULTS: Black, Hispanic, and Asian patients with a primary diagnosis of ICH at discharge were significantly younger, on average, than White patients (73.5 vs. 61.2, 63.9, and 67.9 years, respectively; p < 0.01 for all comparisons). Black and Hispanic patients experienced longer hospital stays (p < 0.01) and incurred higher costs (p < 0.01), on average, than White patients. Among Black and Hispanic patients, adjusted length of stay (mean costs) per discharge were approximately 2.3 days ($1400) and 1.7 ($3400) higher, respectively, as compared to White patients. Asian patients had longer adjusted stays (2.6 additional days, p < 0.01) and higher costs ($830, p < 0.31). CONCLUSIONS: There are meaningful differences in length of stay and cost of ICH hospitalizations among patients with different race/ethnicity. Improved acute treatment of stroke in this high-risk population may help to improve overall outcomes in these subgroups.
HE4 RACIAL/ETHNIC DISPARITIES IN LENGTH OF STAY AND COST OF INPATIENT CARE FOR INTRACEREBRAL HEMORRHAGE: EVIDENCE FROM THE HEALTH CARE COST AND UTILIZATION PROJECT DATABASE

HIGH IMPACT HI1 ADULT ECONOMIC STATUS AND OBESITY IN THE UNITED STATES: 2000-2002
Wu E 1 , Xie J 1 , Crémieux PY 1 , Sullivan PW 2 1 Analysis Group, Inc, Boston, MA, USA, 2 University of Colorado Health Sciences Center, Denver, CO, USA OBJECTIVES:
To assess the association between overweight/obesity and employment to population ratio (E/P Ratio), hourly wage, and annual income in the U.S. METHODS: Adults (age 18-64) in the 2000-2002 Medical Expenditure Panel Survey (MEPS) were classified as normal weight (BMI:18.5-24.9), overweight (BMI:25-29.9), and obese (BMI: >= 30). Underweight (BMI < 18.5) individuals were excluded. E/P ratio, hourly wage, annual income, and poverty status of the overweight and obese adults were compared to that of the normal weight adults, respectively, adjusting for demographic characteristics using a stratification matching method. MEPS sampling weights were applied to ensure nationally representative estimates. The analyses were also conducted for population subgroups defined by gender, race, ethnicity, and physical activity. RESULTS: The study sample includes 35,989 adults, with 13,744 normal weight, 13,321 overweight, and 8,924 obese. The E/P ratio was 87.1% for the overweight sample, 1.8% higher (p < 0.01) than the normal weight sample; and 82.4% for the obese sample, 1.7% lower (p < 0.01) than the normal weight sample. The obese sample made $1.63 less per hour (p < 0.01), and $3338 less annually compared to the normal weight sample (p < 0.01). Compared to the normal weight sample, obese adults were more likely to be poor. No significant difference of annual income and poverty level were found between the overweight and the normal weight sample. Systematic differences between different population subgroups were found. CONCLUSIONS: Obese adults are less likely to be employed, have lower annual incomes and hourly wages, and are more likely to be poor than normal weight adults.
HI2 CLINICAL IMPACT OF PHARMACOTHERAPY VERSUS NON-PHARMACOLOGIC MANAGEMENT AMONG COMMERCIALLY INSURED PERSONS AGED ≥65 YEARS WITH OVERACTIVE BLADDER
Joyce AT 1 , Jumadilova Z 2 , Trocio J 2 , Foltz Boklage S 3 , Girase P 1 1 PharMetrics, a unit of IMS, Watertown, MA, USA, 2 Pfizer, Inc, New York, NY, USA, 3 PharMetrics, a unit of IMS, Fort Washington, PA, USA OBJECTIVE: To examine the incidence of overactive bladder (OAB)-related clinical events for elderly patients receiving pharmacotherapy compared with those receiving non-pharmacologic management. METHODS: Data were obtained from the Phar-Metrics Patient-Centric Database on continuously benefiteligible patients aged ≥65 years diagnosed with OAB between January 2002 and December 2003. Patients were categorized into 2 cohorts: those receiving pharmacotherapy, including longacting tolterodine, or immediate-or extended-release oxybutynin and those receiving non-pharmacologic management. Patients were matched 1 : 1 by the estimated propensity score for OAB pharmacotherapy using a logistic regression model that included selected demographic and clinical characteristics. The incidence of clinical events, including assessment of depression, urinary tract infections (UTIs), and falls or fractures was evaluated. Crude event rates were reported, as well as the risk of an event using Cox proportional hazards models adjusting for important demographic and clinical characteristics. RESULTS: A total of 1681 matched pairs were identified. Mean ± SD age was 78 ± 8 years; 60% were women. After matching, differences in baseline patient characteristics between cohorts were not significant. The incidence of depression (10.2% for pharmacotherapy vs 11.0% for non-pharmacologic management; p = NS) and fractures (8.6% vs 10.1%; p = NS) was numerically lower in the drugtreated cohort, and the incidence of UTI was significantly lower (28.1% vs 36.5%; p < 0.0001). Adjusted rates using Cox proportional hazards models were similar, with no difference in the risk of depression (hazard ratio [HR] = 0.980; 95% confidence interval [CI], 0.795-1.208; p = NS) or fractures (HR = 0.863; 95% CI, 0.691-1.079; p = NS) between the cohorts, and the risk of UTI was 28% lower among pharmacotherapy patients (HR = 0.718; 95% CI, 0.636-0.810; p < 0.0001). CONCLUSIONS: Pharmacotherapy may impart selected clinical benefits for some elderly patients with OAB compared with non-pharmacologic management. Careful consideration should be given to the selection of treatment approaches in this high-risk population.
HI3 THE EFFECTS OF STATIN (HMG-COA REDUCTASE INHIBITOR) COPAYMENTS AND STATIN ADHERENCE ON MEDICAL CARE OUTCOMES AND EXPENDITURES
Gibson TB 1 , Mark T 2 , Axelsen K 3 , Mackell J 4 , King H 3 , Baser O 1 , McGuigan K 3 1 Thomson Medstat, Ann Arbor, MI, USA, 2 Thomson, Washington, DC, USA, 3 Pfizer Global Pharmaceuticals, New York, NY, USA, 4 Pfizer, Inc, New York, NY, USA OBJECTIVES: We examined the effects of statin prescription drug copayments and statin adherence on cardiovascular utilization patterns, medical and prescription drug expenditures and other outcomes of statin therapy. METHODS: The 2001 The -2003 MarketScan database was used to study the health care utilization and expenditure patterns of continuously enrolled statin users in employer sponsored health plans. We analyzed the utilization patterns of 93,296 continuing users who had previously filled at least one statin prescription in 2000 and 24,128 users who were new to statin therapy in the first half of 2001. A two-stage estimation approach consisted of a multivariate logit model estimating the relationship between copay-
